; (B) opportunities for engagement with the Food and Drug Administration with respect to the accelerated approval pathway; (C) considerations for different types of pain and product mechanism of action; and (D) potential criteria for novel surrogate or intermediate clinical endpoints or biomarkers to assess pain. (c) Final guidance Not later than 6 months after the close of the period for public comment on the draft guidance under subsection (b), the Secretary shall finalize such guidance. (d) Data in performance reports (1) In general As a component of the annual performance report under section 736B(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379h–2(a) ), the Secretary shall include information, as appropriate, on policies and processes of the Division of Anesthesia, Analgesia, and Addiction Products of the Food and Drug Administration (referred to in this section as the DAAAP ) for the accelerated approval pathway with respect to drugs developed to treat pain or substance use disorders, during the previous fiscal year. (2) Contents Information submitted as a part of the performance reports under section 736B(a) of the Federal Food, Drug, and Cosmetic Act may address— (A) the number of requests for accelerated approval submitted to the DAAAP for non-opioid or non-addictive medical products; (B) the number of applications for accelerated approval that the DAAAP granted, and a description of the common reasons for granting applications for accelerated approval; (C) the number of applications for accelerated approval that the DAAAP denied, and a description of the common reasons for denying applications for accelerated approval; (D) the percentage of products in such review division which met the review goals identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2017 ( Public Law 115–52 )